Embracing patient empowerment in data collection can lead to new standard of care.
Applied Clinical Trials-10-01-2021
Has technology taken the industry too far?
New support models range from flexible software platforms, IROs, and DROs.
InterveXion CEO Keith Ward and Andrew Schafer, vice president of strategy for Biospatial discuss the details of a study which utilizes EMS data to identify sites for a Phase II clinical trial.
Industry-wide unity paves path for preparedness.
Click the title above for a link to open the Applied Clinical Trials October 2021 issue in an interactive PDF format.
Critics say FDA is either acting too fast and risking public safety—or too slow—mired in rules while ignoring important scientific findings.
Pandemic sparks new advancements in clinical trial development.
Guidance on the unique challenges presented by electronic outcomes.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Seeks Public Input on Early-Phase Clinical Trial Design for Ibogaine
2
Mixed Outsourcing Models Are Spreading. Is Sponsor Oversight Keeping Up?
3
FDA Releases Transparency Roadmap Outlining Disclosure Priorities Across Drug Development and Regulatory Review
4
ACT Brief: Ibogaine Trial Design Guidance, Outsourcing Model Oversight Gaps, and Kidney Disease Partnership
5